Disease/Infection News

RSS

NanoBio to develop intranasal vaccine for HBV

NanoBio® Corporation today announced an initiative to develop an intranasal vaccine for the treatment of hepatitis B (HBV). NanoBio and the University of Michigan's, Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Technology Transfer (STTR) award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients.

20 Apr 2010

Lactobacillus plantarum has no effect on Salmonella: University of Gothenburg

Many tourists travelling abroad go down with diarrhoea, which can be caused by Salmonella. While probiotics are often cited as the solution to various stomach problems, the probiotic, Lactobacillus plantarum has no effect on Salmonella, reveals a new thesis at the University of Gothenburg, Sweden.

20 Apr 2010

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

Though the world has made "great strides" in eliminating H5N1 (avian flu) from poultry since the "peak of its outbreak in 2006" in 63 countries, the virus persists in Bangladesh, China, Egypt, Indonesia and Vietnam, VOA News reports (DeCapua, 4/16).

20 Apr 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

Opinions: PEPFAR; Private-civil society partnerships in Africa; Global maternal mortality; SA HIV testing campaign

"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.

20 Apr 2010

New research shows link between infection-related diseases and risk of cancer

New research is emerging that suggests a link between infection-related diseases and risk of cancer, according to findings presented here at the American Association for Cancer Research 101st Annual Meeting 2010.

20 Apr 2010

Gilead Sciences halts Phase II trial of GS 9450 for chronic hepatitis C

Gilead Sciences, Inc. today announced the company is stopping its ongoing Phase II clinical trial of GS 9450, an investigational caspase inhibitor, in patients with chronic hepatitis C. This decision follows reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.

20 Apr 2010

Novartis withdraws EMA MAA for JOULFERON

Human Genome Sciences, Inc. today announced that Novartis has withdrawn a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C.

19 Apr 2010

BioMarin Pharmaceutical introduces Firdapse for LEMS in the E.U.

BioMarin Pharmaceutical Inc. announced today that Firdapse™ (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Launching immediately in Germany and the UK, the company expects to subsequently launch Firdapse in all major European markets by the end of 2010.

19 Apr 2010

Matrix Laboratories' ANDA for Didanosine Delayed-release Capsules receives FDA approval under PEPFAR

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.

19 Apr 2010

Resistance to antibiotics on the increase in intestinal bacteria in animals: Study

Anne-Mette R. Grønvold has through her doctoral research shown that resistance to antibiotics is on the increase in intestinal bacteria in animals as a direct result of antibiotic treatments. The antibiotics also alter the composition of bacteria in the intestines.

19 Apr 2010

Researchers reveal new switch to Salmonella bacteria: Science

A new switch that enables Salmonella bacteria to sabotage host cells is revealed in a study published today in the journal Science.

19 Apr 2010

New in vitro study results of Hydrofiber dressing to be presented at SAWC/WHS 2010

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results in which a Hydrofiber dressing containing ionic silver was observed to conform more closely to a porcine tissue surface in a shallow wound model than did certain silver-containing foam dressings following hydration.

19 Apr 2010

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

Protein Potential LLC has received support from the National Institute of Allergy and Infectious Diseases of the NIH in the form of a Phase II Small Business Innovation Research Grant. The three-year award totaling approximately $3 million will support translational research to develop a vaccine for the prevention of malaria caused by the parasite Plasmodium vivax.

19 Apr 2010

Enhancing drug residence time may help develop better diagnostic, therapeutic agents

Research conducted at the Stony Brook University Institute for Chemical Biology & Drug Discovery that enhances the time a drug remains bound to its target, or residence time, may prove to be an important step in developing better diagnostic and therapeutic agents based partly on longer drug residence time.

17 Apr 2010

700 scientists to present new information on smell and taste at AChemS 32nd annual meeting

The Association for Chemoreception Sciences (AChemS), a US-based scientific organization, is holding its 32nd annual meeting. About 700 scientists are gathering to present new information on the role of smell and taste in disease, nutrition and social interactions in humans as well as animals. Smell and taste play essential roles in our daily lives. These chemical senses serve as important warning systems, alerting us to the presence of potentially harmful situations or substances, including gas leaks, smoke, and spoiled food.

17 Apr 2010

WHO issues guidance on ash cloud from Iceland volcanic explosion

The ash cloud from the volcanic explosion in Iceland contains fine particles, similar to those emitted from other sources of particulate matter (PM); but as long as ash remains in the upper atmosphere, there will not likely be an increased risk of health effects, according to WHO.

17 Apr 2010

Project to integrate data from climate modelling, disease forecasting systems for predicting epidemics

Researchers across 13 European and African research institutes will work together to integrate data from climate modelling and disease forecasting systems to predict the likelihood of an epidemic up to six months in advance. The research, funded by the European Commission Seventh Framework programme, will focus on climate and disease in Senegal, Ghana and Malawi and aims to give decision makers the necessary time to deploy intervention methods to help prevent large scale spread of diseases such as Rift Valley Fever and malaria.

17 Apr 2010

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

24 weeks of treatment could be sufficient to cure between 93 and 100% of treatment-na-ve chronic hepatitis C virus (HCV) genotype 1 (G1) infected patients if they have a fast antiviral response to Telaprevir (TVR) with Peginterferon (PEG-IFN) and Ribavirin (RBV), according to new research presented today at the International Liver Congress 2010, the Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria.

17 Apr 2010

Pennsylvania awarded $1M in Recovery Act funding for managing chronic disease in older citizens

Governor Edward G. Rendell today announced that $1 million from the American Recovery and Reinvestment Act has been awarded to Pennsylvania to prevent and manage chronic disease in older citizens.

17 Apr 2010

Disease/Infection News

NanoBio to develop intranasal vaccine for HBV

Lactobacillus plantarum has no effect on Salmonella: University of Gothenburg

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

Opinions: PEPFAR; Private-civil society partnerships in Africa; Global maternal mortality; SA HIV testing campaign

New research shows link between infection-related diseases and risk of cancer

Gilead Sciences halts Phase II trial of GS 9450 for chronic hepatitis C

Novartis withdraws EMA MAA for JOULFERON

BioMarin Pharmaceutical introduces Firdapse for LEMS in the E.U.

Matrix Laboratories' ANDA for Didanosine Delayed-release Capsules receives FDA approval under PEPFAR

Resistance to antibiotics on the increase in intestinal bacteria in animals: Study

Researchers reveal new switch to Salmonella bacteria: Science

New in vitro study results of Hydrofiber dressing to be presented at SAWC/WHS 2010

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

Enhancing drug residence time may help develop better diagnostic, therapeutic agents

700 scientists to present new information on smell and taste at AChemS 32nd annual meeting

WHO issues guidance on ash cloud from Iceland volcanic explosion

Project to integrate data from climate modelling, disease forecasting systems for predicting epidemics

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

Pennsylvania awarded $1M in Recovery Act funding for managing chronic disease in older citizens

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News